$16.49
−0.12%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$16.54
From 52W high−11.44%
Volume552179.00
Market cap$2.19B
P/E (TTM)7.0x
P/S (TTM)7.0x
Div yield—
Key dataOct 19, 2026
Open
$16.54
From 52W high
−11.44%
Volume
552179.00
Market cap
$2.19B
ValuationView details →
P/E (Fwd)
22.9x
EV/EBITDA
9.6x
P/E (TTM)
7.0x
RSI (14)
54.0
MomentumView details →
1D Return
−0.12%
YTD Return
+3.70%
SummaryUpdated Jun 1, 2026
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a commercial-stage biopharmaceutical company founded in 1993 and headquartered in Victoria, Canada. The company went public in 2014 and has evolved from a research-focused biotech into a commercial enterprise following the approval of its lead drug LUPKYNIS in 2021. Aurinia specializes in developing therapies for autoimmune diseases with significant unmet medical needs, particularly focusing on lupus nephritis, a severe kidney complication affecting lupus patients. The company has successfully transitioned from a loss-making development-stage company to profitability, generating over $235 million in revenue in 2024.
Similar companies
Latest newsMore news →
LB Pharmaceuticals Inc. appointed Joseph M. Miller as Chief Financial Officer, effective September 2, 2026, with an annual base salary of $530,000 and a target bonus of 40% of base salary.47d agoAurinia Pharmaceuticals settled patent litigation with Teva Pharmaceuticals, resolving the dispute between the two companies.61d ago